Glow Lifetech Past Earnings Performance
Past criteria checks 0/6
Glow Lifetech has been growing earnings at an average annual rate of 16.4%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 155.3% per year.
Key information
16.4%
Earnings growth rate
32.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 155.3% |
| Return on equity | n/a |
| Net Margin | -412.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Glow Lifetech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -1 | 1 | 0 |
| 31 Mar 24 | 0 | -2 | 1 | 0 |
| 31 Dec 23 | 0 | -2 | 1 | 0 |
| 30 Sep 23 | 0 | -2 | 1 | 0 |
| 30 Jun 23 | 0 | -2 | 1 | 0 |
| 31 Mar 23 | 0 | -2 | 1 | 0 |
| 31 Dec 22 | 0 | -2 | 1 | 0 |
| 30 Sep 22 | 0 | -1 | 1 | 0 |
| 30 Jun 22 | 0 | -1 | 1 | 0 |
| 31 Mar 22 | 0 | -2 | 2 | 0 |
| 31 Dec 21 | 0 | -11 | 5 | 0 |
| 30 Sep 21 | 0 | -12 | 5 | 0 |
| 30 Jun 21 | 0 | -13 | 5 | 0 |
| 31 Mar 21 | 0 | -12 | 4 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | -2 | 1 | 0 |
| 30 Jun 20 | 0 | -1 | 1 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
Quality Earnings: 9DO is currently unprofitable.
Growing Profit Margin: 9DO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 9DO is unprofitable, but has reduced losses over the past 5 years at a rate of 16.4% per year.
Accelerating Growth: Unable to compare 9DO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 9DO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 9DO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.